Covaxin, India’s homegrown COVID jab, ‘highly efficacious’: Study
Data from Phase 3 trials show vaccine offers 78 percent protection against COVID-19, says a study published in Lancet.Data from Phase 3 trials show vaccine offers 78 percent protection against COVID-19, says a study published in Lancet.